Abstract Background/Aims: The function of BRAF V600E as a prognostic biomarker
continues controversial by reason of conflicting results in the published articles. Methods: A …

Introduction: There have been contradictory data on whether or not BRAF V600E mutation
should be regard as a poor prognosis predictor of papillary thyroid carcinoma (PTC). To …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …

Background The objective of this study is to perform a meta-analysis to evaluate the
associations between the BRAF V600E mutation status and aggressive clinicopathological …

BACKGROUND. Numerous studies have investigated the clinical significance of BRAF
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …

Background. Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC)
worldwide has been increasing rapidly year by year, with the incidence rate increasing 6 …

Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC
is an epithelial tumor characterized by the proliferation of follicular cells with distinctive …

Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …

Abstract Background The BRAF V600E mutation is the most common genetic alteration
found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more …

Background. The BRAF V600E mutation is an important genetic event in papillary thyroid
cancer (PTC). This study aimed to provide additional information regarding the association …